Hemogenyx Pharmaceuticals Plc (HOPHF)
- Previous Close
0.0400 - Open
0.0400 - Bid 0.0031 x --
- Ask 1.0000 x --
- Day's Range
0.0400 - 0.0400 - 52 Week Range
0.0031 - 0.0400 - Volume
25,000 - Avg. Volume
2,015 - Market Cap (intraday)
28.999M - Beta (5Y Monthly) 3.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Sep 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
hemogenyx.comRecent News: HOPHF
View More
Performance Overview: HOPHF
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOPHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOPHF
View MoreValuation Measures
Market Cap
28.79M
Enterprise Value
30.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.02
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.79%
Return on Equity (ttm)
-155.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.18M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.64M
Total Debt/Equity (mrq)
92.09%
Levered Free Cash Flow (ttm)
-2.73M
Company Insights: HOPHF
HOPHF does not have Company Insights